Disease Overview：Aortic stenosis（AS）
Aortic stenosis is a progressive valvular heart disease characterized by narrowing of the aortic valve orifice, impeding blood flow from the left ventricle to the aorta. It commonly results from age-related calcification in older adults, congenital bicuspid aortic valve in younger patients, or rheumatic heart disease in endemic regions. Symptoms—such as exertional dyspnea, angina, syncope, and heart failure—typically emerge once the valve area falls below 1.0 cm² and transvalvular gradient exceeds 40 mmHg. Untreated severe aortic stenosis carries a poor prognosis, with median survival of only 2–3 years after symptom onset. Diagnosis relies on echocardiography (including Doppler assessment of peak velocity, mean gradient, and calculated valve area), supplemented by cardiac CT or MRI when anatomical detail or coronary evaluation is needed. Treatment hinges on severity and symptom status: asymptomatic patients require close monitoring, while symptomatic severe cases necessitate intervention—either surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI), depending on surgical risk profile and anatomical suitability.
China offers compelling advantages for international patients seeking aortic stenosis management. The country hosts numerous nationally accredited cardiovascular centers with Level-IV TAVI certification, led by physicians trained at leading Western institutions and actively contributing to global clinical trials. Advanced imaging platforms—including 3D/4D echocardiography, high-resolution CT angiography, and intraoperative fusion imaging—are standard across top-tier hospitals. Over 15,000 TAVI procedures were performed in China in 2023 alone, with reported 30-day mortality rates under 2.5% and 1-year survival exceeding 92% in low-to-intermediate-risk cohorts. Crucially, treatment costs—including comprehensive preoperative workup, procedure, hospitalization, and follow-up—are typically 40–60% lower than in the US or Western Europe, without compromising clinical standards or regulatory oversight. As a dedicated medical tourism agency, we facilitate seamless access to these resources: vetting JCI-accredited hospitals, coordinating multidisciplinary consultations, providing transparent all-inclusive pricing, arranging visas and accommodation, and offering bilingual clinical support throughout the care journey—from initial evaluation to post-discharge rehabilitation planning.
Aortic stenosis: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Aortic Stenosis (Cardiovascular Department)
Non-Surgical / Conservative Management
*Indicated for asymptomatic mild-to-moderate AS or patients unfit for intervention.*
- •Monitoring & Lifestyle Guidance: Annual echocardiogram + clinical assessment
- ECG + Chest X-ray: $35–$50 - NT-proBNP + Lipid Panel + Renal Function (Cr, eGFR): $65–$95
- •Medication Support (symptom control only; *no disease-modifying drugs*):
- •*No pharmacotherapy reverses stenosis or improves survival in severe AS.*
Surgical & Interventional Options
*Eligibility requires confirmed severe AS (aortic valve area ≤1.0 cm², mean gradient ≥40 mmHg, peak velocity ≥4.0 m/s) + symptoms or high-risk features.*
- •Surgical Aortic Valve Replacement (SAVR)
- Procedure (mechanical/bioprosthetic valve): $14,500–$22,000 - Pre-op workup (TTE, TEE, coronary angiography, pulmonary function, CT aortogram): $2,100–$3,300
- •Transcatheter Aortic Valve Implantation (TAVI/TAVR)
- Procedure (self-expanding or balloon-expandable valve): $28,000–$41,000 - Pre-op workup (CT angiography mandatory + TTE/TEE + vascular ultrasound): $2,400–$3,600
Special/Complex Condition Options
- •Low-Flow, Low-Gradient Severe AS with Reduced LVEF: Dobutamine stress echo + advanced hemodynamics → SAVR preferred if contractile reserve present: + $420 (stress echo fee)
- •Bicuspid Aortic Valve with Ascending Aorta >4.5 cm: Combined aortic root replacement + AVR → adds $8,500–$12,000 to SAVR cost
- •Concomitant Coronary Artery Disease: SAVR + CABG → adds $4,800–$7,200
Quick Selection Guide
- •<75 years, low surgical risk, no frailty: SAVR — optimal durability, lowest long-term cost ($16,600–$25,300 total)
- •≥75 years or high surgical risk (e.g., COPD, prior sternotomy, porcelain aorta): TAVI — superior safety, faster recovery ($30,400–$44,600 total)
- •Asymptomatic severe AS with rapid progression (ΔAVA <0.1 cm²/year): Accelerated monitoring (q6mo TTE + BNP) — $240–$360/year, defer intervention until symptom onset
- •Severe AS + end-stage renal disease on dialysis: TAVI via transcarotid/transapical route — $33,000–$46,000, requires multidisciplinary nephrology-cardiology coordination
- •Budget-constrained (<$20,000): SAVR remains only evidence-based curative option; conservative management is *not* cost-effective long-term due to high 2-year mortality (>50%) in symptomatic severe AS.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Aortic stenosis Medical Vacation Packages
Curated transparent all-inclusive packages combining Aortic stenosis treatment with China top medical destinations:
